A
Alcista
Alcista · 25%LNTH
$109.31
Precio del escenario
$99.700
-0.289 (-0.29%)Al cierre
Loading chart…
- Máximo
- 100.280
- Apertura
- 100.090
- Precio medio ponderado por volumen
- 99.86
- Volumen
- 1.71M
- Capitalización
- 5.64B
- Mínimo
- 99.595
- Importe
- 170.92M
- EV/EBITDA, TTM
- 12.73
Lantheus Holdings, Inc. is a radiopharmaceutical-focused company, dedicated to helping clinicians find, fight, and follow disease to deliver better patient outcomes. Its product categories include oncology, neurology, cardiology, and strategic partnerships and others. Its products include PYLARIFY, Neuraceq, and DEFINITY. PYLARIFY TruVu is indicated for PET imaging of PSMA-positive lesions in men with prostate cancer with suspected metastasis who are candidates for initial definitive therapy, or suspected recurrence based on elevated serum prostate-specific antigen (PSA). Neuraceq is an Alzheimer's disease radiodiagnostic. Its commercial products are used by cardiologists, internists, neurologists, nuclear medicine physicians, oncologists, radiologists, sonographers, technologists, and urologists across a range of clinical care settings. Its diagnostic products provide information that enables healthcare professionals (HCPs) to better detect, characterize, or rule out diseases.
Análisis de IA of Lantheus Holdings Inc (LNTH)
MantenerLantheus Holdings Inc is currently priced at $99.70, which is below the analyst price target of $102.50, indicating potential for short-term gains. However, the RSI is at 28.051, suggesting the stock is oversold and may not have immediate upward momentum. The recent acquisition news by Curium for $102.50 per share adds a layer of uncertainty, as the stock is now more influenced by this deal than its fundamentals. Given the downgrade by multiple analysts and the significant hedge fund selling activity (up 2127.26%), it is prudent to hold rather than buy at this moment.
Recomendaciones de analistas (4)
-17.58% Potencial de caída
Comprar
3 Comprar
1 Mantener
0 Vender
Actual: 99.70
Mínimo
70.00
Promedio
82.17
Máximo
105.00
CJS Securities
Market Perform
$102.50
2026-08-04
CJS Securities
2026-08-04
Precio objetivo
$102.50
Market Perform
Truist
Mantener
$125
2026-08-03
Truist
2026-08-03
Precio objetivo
$125
Mantener
Leerink
Market Perform
$102.50
2026-08-03
Leerink
2026-08-03
Precio objetivo
$102.50
Market Perform
TD Cowen
Mantener
$110
2026-08-03
TD Cowen
2026-08-03
Precio objetivo
$110
Mantener
William Blair
Market Perform
$5.00
2026-08-03
William Blair
2026-08-03
Precio objetivo
$5.00
Market Perform
Métricas de valoración
El PER previsto actual de Lantheus Holdings Inc (LNTH) es 14.27, frente a su media de 5 años de 14.63.
Escenarios de precio de Alphio AI para LNTH
Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.
Ballenas con LNTH en cartera
Cronología de eventos
Noticias
7.009-29PRnewswireInvestor Rights Law Firm Investigates Multiple Companies
9.009-22NASDAQ.COMLantheus Secures FDA Approval for Bravnetsa Radiopharmaceutical
7.009-11PRnewswireInvestor Rights Law Firm Investigates Multiple Companies
7.008-07PRnewswireInvestor Rights Law Firm Investigates Multiple Companies for Potential Violations
9.008-03stocktwitsFDA Approval Updates for Biotech Companies
Preguntas frecuentes sobre LNTH, respondidas por Alphio AI
Lantheus Holdings, Inc. is a radiopharmaceutical-focused company, dedicated to helping clinicians find, fight, and follow disease to deliver better patient outcomes. Its product categories include oncology, neurology, cardiology, and strategic partnerships and others. Its products include PYLARIFY, Neuraceq, and DEFINITY. PYLARIFY TruVu is indicated for PET imaging of PSMA-positive lesions in men with prostate cancer with suspected metastasis who are candidates for initial definitive therapy, or suspected recurrence based on elevated serum prostate-specific antigen (PSA). Neuraceq is an Alzheimer's disease radiodiagnostic. Its commercial products are used by cardiologists, internists, neurologists, nuclear medicine physicians, oncologists, radiologists, sonographers, technologists, and urologists across a range of clinical care settings. Its diagnostic products provide information that enables healthcare professionals (HCPs) to better detect, characterize, or rule out diseases. It operates in the Healthcare sector (IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES industry).
Lantheus Holdings Inc is currently priced at $99.70, which is below the analyst price target of $102.50, indicating potential for short-term gains. However, the RSI is at 28.051, suggesting the stock is oversold and may not have immediate upward momentum. The recent acquisition news by Curium for $102.50 per share adds a layer of uncertainty, as the stock is now more influenced by this deal than its fundamentals. Given the downgrade by multiple analysts and the significant hedge fund selling activity (up 2127.26%), it is prudent to hold rather than buy at this moment.
4 analysts cover LNTH: 3 rate it Buy, 1 Hold and 0 Sell. The average price target is 82.17.
Comunidad
Más ↗Aún no hay publicaciones
Regístrate o inicia sesión para participarEsta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.